A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Glucagon-like peptide-1 receptor (GLP-1R), a class B1 G protein-coupled receptor, plays critical roles in glucose homeostasis. Recent structural pharmacology studies using cryogenic electron microscopy, X-ray crystallography, mass spectrometry, and f…
Bimagrumab is a monoclonal antibody that targets activin type II receptors, blocks myostatin and related proteins: it promotes muscle growth and prevents muscle loss, while causing weight loss. It has been effective in sporadic inclusion body myositi…
BACKGROUND: The introduction of incretin mimetics (IMs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as liraglutide and semaglutide, as well as dual GLP-1/glucose-dependent insulinotropic polypeptide receptor co-agonists (GLP…
Euglycemic diabetic ketoacidosis (EDKA) is an uncommon life-threatening condition increasingly recognized in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Its diagnosis is often delayed due to the absence of significant hy…
BACKGROUND: We retrospectively evaluated the efficacy of using additional obesity management medications (OMMs) within the first year after undergoing laparoscopic sleeve gastrectomy (LSG). METHODS: We retrospectively analyzed 246 patients who underw…
Semaglutide (Ozempic®), administered as a weekly subcutaneous injection up to 1.0 mg, holds a privileged place in the international guidelines for the management of type 2 diabetes. Commercialized under the trade name Wegovy®, semaglutide is also ind…
INTRODUCTION: Most epidemiological studies have found antibiotics to be the most common cause of drug-induced liver injury (DILI). It is unclear what the risk of DILI is associated with different antibiotics. OBJECTIVE: The aim of the study was to as…
Alzheimer's disease (AD) is the most common cause of cognitive decline. Among the various susceptibility genes, the gene of apolipoprotein E () is probably the most important. It may be present in three allelic forms, termed ε2, ε3 and ε4, and the mo…
The follicular occlusion tetrad is a chronic inflammatory complex that consists of four co-related conditions in which follicles are blocked with keratin rupture and lead to inflammation. These conditions include hidradenitis suppurativa (HS), acne c…
BACKGROUND: GLP-1 receptor agonists (GLP-1RAs) are increasingly prescribed for diabetes and obesity management. Recent pharmacovigilance reports have raised concerns about potential neuropsychiatric adverse events, yet comprehensive safety assessment…
This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications…
Erectile dysfunction (ED) is a common yet frequently underrecognized microvascular complication of diabetes, affecting up to three out of four individuals. Key contributing factors include advancing age, long-standing disease duration, and suboptimal…
Obesity, type 2 diabetes mellitus and associated thyroid diseases are most common among elderly patients. Glucagon-like peptide-1 receptor (GLP-1-R) agonists, including semaglutide, are a promising approach for their treatment, but their effects on m…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RAs) lead to substantial weight loss and pain reduction in persons with knee osteoarthritis and obesity. OBJECTIVE: To evaluate the cost-effectiveness of 2 GLP1RAs, semaglutide and tirzepatid…
Obesity is a chronic, multifactorial metabolic disease associated with various factors such as insulin resistance, increased adipogenesis, induction of gluconeogenesis, epigenetic mechanisms, chronic inflammatory state, and oxidative stress. Anti-obe…
OBJECTIVES: To identify novel targets to treat obesity, we focused on the equilibrative nucleoside transporter 1 (ENT1), which is a key regulator of extracellular adenosine levels in adipose tissue. Adenosine has been shown to control multiple aspect…
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated substantial efficacy in managing type 2 diabetes mellitus (T2DM). It provides glycemic control, promotes weight loss, and offers cardiovascular protection. Evidence a…